Akero Therapeutics Stock Price, News & Analysis (NASDAQ:AKRO) $19.77 +0.71 (+3.73%) (As of 12/7/2023 ET) Add Compare Share Share Today's Range$18.99▼$20.0750-Day Range$11.38▼$50.5852-Week Range$11.25▼$58.38Volume1.14 million shsAverage Volume987,007 shsMarket Capitalization$1.10 billionP/E RatioN/ADividend YieldN/APrice Target$40.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Akero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.7% Upside$40.86 Price TargetShort InterestBearish11.04% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.67Based on 5 Articles This WeekInsider TradingSelling Shares$2.08 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.81) to ($3.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector163rd out of 960 stocksPharmaceutical Preparations Industry41st out of 381 stocks 4.5 Analyst's Opinion Consensus RatingAkero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.86, Akero Therapeutics has a forecasted upside of 106.7% from its current price of $19.77.Amount of Analyst CoverageAkero Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.04% of the outstanding shares of Akero Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkero Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akero Therapeutics has recently increased by 4.41%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAkero Therapeutics does not currently pay a dividend.Dividend GrowthAkero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkero Therapeutics has received a 75.57% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akero Therapeutics is -0.75. Previous Next 2.6 News and Social Media Coverage News SentimentAkero Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Akero Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for AKRO on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akero Therapeutics insiders have sold 146.08% more of their company's stock than they have bought. Specifically, they have bought $845,000.00 in company stock and sold $2,079,377.00 in company stock.Percentage Held by InsidersOnly 9.69% of the stock of Akero Therapeutics is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Akero Therapeutics are expected to decrease in the coming year, from ($2.81) to ($3.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akero Therapeutics is -8.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akero Therapeutics is -8.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkero Therapeutics has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akero Therapeutics Stock (NASDAQ:AKRO)Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Read More AKRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKRO Stock News HeadlinesDecember 7, 2023 | americanbankingnews.comG. Walmsley Graham Acquires 50,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockDecember 6, 2023 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up on Insider Buying ActivityDecember 8, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 3, 2023 | americanbankingnews.comAkero Therapeutics (NASDAQ:AKRO) Trading Down 3.1%December 2, 2023 | seekingalpha.comAMKR, ALKS and CLFD are among after hour moversNovember 23, 2023 | morningstar.comAkero Therapeutics Inc AKRONovember 22, 2023 | seekingalpha.comAkero Therapeutics: Deceptively PromisingNovember 15, 2023 | markets.businessinsider.comEd Arce’s Buy Rating for Akero Therapeutics: Anticipated Success with SYNCHRONY Studies and EFX Drug DevelopmentsDecember 8, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 15, 2023 | benzinga.comAkero Therapeutics Stock (NASDAQ:AKRO) Earnings Dates and Earning CallsNovember 14, 2023 | finance.yahoo.comAkero Therapeutics Inc (AKRO) Reports Q3 2023 Financial ResultsNovember 14, 2023 | markets.businessinsider.com11 Analysts Have This to Say About Akero TherapeuticsNovember 13, 2023 | benzinga.comAkero Therapeutics: Q3 Earnings InsightsNovember 13, 2023 | finance.yahoo.comAkero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 12, 2023 | stockhouse.comAkero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting® 2023November 10, 2023 | finance.yahoo.comAkero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023October 17, 2023 | finance.yahoo.comAkero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor ConferenceOctober 13, 2023 | msn.comUBS Maintains Akero Therapeutics (AKRO) Buy RecommendationOctober 12, 2023 | fool.comAkero Therapeutics (NASDAQ: AKRO)October 11, 2023 | finance.yahoo.comAkero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path ForwardOctober 11, 2023 | markets.businessinsider.comOptimistic Outlook for Akero Therapeutics’ EFX Despite SYMMETRY Study Setback: Dolezal’s PerspectiveOctober 10, 2023 | msn.comAkero slumps leading to mixed reactions in NASH spaceOctober 10, 2023 | markets.businessinsider.comAkero Therapeutics' Disappointing NASH Data Drags Its RivalOctober 10, 2023 | finance.yahoo.comWhy Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bioOctober 10, 2023 | finance.yahoo.comWhy Shares of 89bio Plummeted on TuesdayOctober 10, 2023 | msn.comAkero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' DataOctober 10, 2023 | markets.businessinsider.comWhy Is Liver Disease Focused Akero Therapeutics Stock Sinking Today?See More Headlines Receive AKRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/07/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKRO CUSIPN/A CIK1744659 Webwww.akerotx.com Phone(650) 487-6488FaxN/AEmployees51Year FoundedN/APrice Target and Rating Average Stock Price Target$40.86 High Stock Price Target$58.00 Low Stock Price Target$33.00 Potential Upside/Downside+106.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.11% Return on Assets-23.87% Debt Debt-to-Equity Ratio0.04 Current Ratio20.25 Quick Ratio20.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.98 per share Price / Book2.83Miscellaneous Outstanding Shares55,710,000Free Float50,312,000Market Cap$1.10 billion OptionableNot Optionable Beta-0.50 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Andrew Cheng M.D. (Age 56)Ph.D., President, CEO & Director Comp: $1.22MDr. Jonathan M. Young J.D. (Age 53)Ph.D., Co-Founder, Executive VP, COO & Secretary Comp: $763.3kDr. Timothy Rolph (Age 69)Co-Founder & Chief Scientific Officer Comp: $819.4kMr. William R. White J.D. (Age 50)Executive VP, CFO, Treasurer & Head of Corporate Development Comp: $768.4kMs. Catriona Yale (Age 51)Executive VP & Chief Development Officer Comp: $754.8kMr. Patrick Lamy (Age 50)Senior Vice President of Commercial Strategy Mr. John J. Schembri (Age 61)VP of Finance & Controller More ExecutivesKey CompetitorsANI PharmaceuticalsNASDAQ:ANIPLigand PharmaceuticalsNASDAQ:LGNDMorphoSysNASDAQ:MORMannKindNASDAQ:MNKDDay One BiopharmaceuticalsNASDAQ:DAWNView All CompetitorsInsiders & InstitutionsCitigroup Inc.Sold 28,100 shares on 12/6/2023Ownership: 0.000%Wellington Management Group LLPSold 72,244 shares on 12/1/2023Ownership: 1.488%G. Walmsley GrahamBought 50,000 shares on 11/30/2023Total: $845,000.00 ($16.90/share)Deutsche Bank AGSold 63,951 shares on 11/24/2023Ownership: 0.199%Walleye Trading LLCSold 29,700 shares on 11/21/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions AKRO Stock Analysis - Frequently Asked Questions Should I buy or sell Akero Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKRO shares. View AKRO analyst ratings or view top-rated stocks. What is Akero Therapeutics' stock price target for 2024? 8 analysts have issued 12 month price objectives for Akero Therapeutics' stock. Their AKRO share price targets range from $33.00 to $58.00. On average, they expect the company's share price to reach $40.86 in the next year. This suggests a possible upside of 106.7% from the stock's current price. View analysts price targets for AKRO or view top-rated stocks among Wall Street analysts. How have AKRO shares performed in 2023? Akero Therapeutics' stock was trading at $54.80 at the beginning of 2023. Since then, AKRO stock has decreased by 63.9% and is now trading at $19.77. View the best growth stocks for 2023 here. When is Akero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024. View our AKRO earnings forecast. How were Akero Therapeutics' earnings last quarter? Akero Therapeutics, Inc. (NASDAQ:AKRO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01. What ETFs hold Akero Therapeutics' stock? ETFs with the largest weight of Akero Therapeutics (NASDAQ:AKRO) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Invesco DWA SmallCap Momentum ETF (DWAS). What other stocks do shareholders of Akero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akero Therapeutics investors own include Fulcrum Therapeutics (FULC), Kaleido Biosciences (KLDO), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Gossamer Bio (GOSS), Provention Bio (PRVB), Alector (ALEC), Micron Technology (MU), VIVUS (VVUS). When did Akero Therapeutics IPO? (AKRO) raised $75 million in an IPO on Thursday, June 20th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Evercore ISI served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Akero Therapeutics' major shareholders? Akero Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alkeon Capital Management LLC (6.78%), FMR LLC (4.95%), Adage Capital Partners GP L.L.C. (3.49%), Redmile Group LLC (3.18%), Rock Springs Capital Management LP (2.55%) and Wellington Management Group LLP (1.49%). Insiders that own company stock include Andrew Cheng, Catriona Yale, G Walmsley Graham, Jonathan Young, Kevin Bitterman, Seth Loring Harrison, Skorpios Trust, Timothy Rolph, Tomas J Heyman and William Richard White. View institutional ownership trends. How do I buy shares of Akero Therapeutics? Shares of AKRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:AKRO) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.